Molecular Characterization of High-Grade Gliomas

High-grade gliomas are aggressive brain tumours defined by distinct molecular alterations that guide diagnosis, prognosis and therapeutic strategies. Integrative genomic and epigenomic analyses have delineated key subgroups: IDH-mutant gliomas, which exhibit a CpG island methylator phenotype and improved survival, and IDH-wildtype glioblastomas, frequently harbouring EGFR amplification, TERT promoter mutations and PTEN loss. Paediatric high-grade gliomas diverge from adult forms, featuring oncohistone mutations in H3F3A—principally K27M and G34R/V—that remodel chromatin landscapes, repress DNA repair pathways and shape tumour identity. DNA methylation profiling, transcriptomic signatures and copy-number analyses now underlie the WHO classification, uncovering novel entities and refining risk stratification. Epigenetic dysregulation at telomeric and promoter CpG islands, coupled with receptor tyrosine kinase alterations such as PDGFRA amplification, defines actionable vulnerabilities. Single-cell and spatial omics have revealed intratumoural heterogeneity and microenvironmental interactions that drive therapeutic resistance. These advances have spurred targeted approaches—including mutant IDH inhibitors, EGFR tyrosine kinase inhibitors, PARP inhibitors, histone deacetylase inhibitors and immunomodulators—while enabling precise molecular diagnostics worldwide. Ongoing multi-omic efforts aim to translate these insights into personalised treatment regimens and improved clinical outcomes for patients with these formidable tumours.

Research from Nature Portfolio

Whole-genome bisulphite sequencing of gliomas with H3.3-G34R/V mutations identified a unique methylation signature, distinguishing these tumours from K27M-mutant and H3-wildtype counterparts. Notably, hypermethylated CpG islands encompassed oligodendrocyte lineage transcription factors and histone gene clusters, implicating oncohistone-driven epigenomic reprogramming in gliomagenesis. CRISPR/Cas9-mediated disruption of the mutant G34 allele in a glioma cell line reversed a subset of these methylation changes, directly linking the oncohistone mutation to aberrant methylome architecture. This foundational work establishes the central role of histone-mutant methylomic alterations as drivers of tumour identity and potential therapeutic targets.

Molecular Characterization of High-Grade Gliomas publication trend

The graph below shows the total number of articles in molecular characterization of high-grade gliomas across all publications each year (not limited to Nature Index journals).

Technical terms

Oncohistone: A mutated histone protein (e.g., H3.3-G34R/V, H3-K27M) that perturbes chromatin structure and gene regulation.

CpG island: A genomic region rich in cytosine–guanine dinucleotides often located near gene promoters and susceptible to methylation.

DNA methylation profiling: A method to assess genome-wide patterns of methylation, used to classify tumours and identify epigenetic biomarkers.

PARP inhibitor: A drug that impairs poly(ADP-ribose) polymerase-mediated DNA repair, sensitising tumours to DNA-damaging therapies.

cGAS/STING pathway: An innate immune sensing cascade activated by cytosolic DNA that induces type I interferon production and antitumour immunity.

References

1. Rare Pediatric Cerebellar High-Grade Gliomas Mimic Medulloblastomas Histologically and Transcriptomically and Show p53 Mutations. Cancers (2024).
2. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. Journal of Clinical Investigation (2022).
3. High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?. Journal of Translational Medicine (2022).
4. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors. Scientific Reports (2020).